NCT03276988View on ClinicalTrials.gov

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

January 20, 2020

Study Completion Date

January 20, 2020

Conditions
Total ThyroidectomyNear-total Thyroidectomy
Interventions
DRUG

Period 1 GX-30, Period 2 THYROGEN®

Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.

DRUG

Period 1 THYROGEN®, Period 2 GX-30

Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.

Trial Locations (5)

16499

Ajou University Hospital, Suwon

49241

Pusan National University Hospital, Busan

02841

Korea University Anam Hospital, Seoul

05505

Seoul Asan Medical Center, Seoul

06591

Seoul St. Mary's Hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
collaborator

Symyoo

INDUSTRY

lead

Genexine, Inc.

INDUSTRY

NCT03276988 - Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients | Biotech Hunter | Biotech Hunter